Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Measuring the Value of Pharmaceuticals in the US Health System.

Literature DB >> 27785770

Measuring the Value of Pharmaceuticals in the US Health System.

Surrey M Walton¹, Anirban Basu², John Mullahy³, Samuel Hong⁴, Glen T Schumock⁵.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2017 PMID： 27785770 PMCID： PMC6590687 DOI： 10.1007/s40273-016-0463-3

Source DB: PubMed Journal: Pharmacoeconomics ISSN： 1170-7690 Impact factor: 4.981

Keyword Cloud
References

× No keyword cloud information.

25 in total

1. Value-Based Payments Require Valuing What Matters to Patients.

Authors: Joanne Lynn; Aaron McKethan; Ashish K Jha
Journal: JAMA Date: 2015-10-13 Impact factor: 56.272

2. New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines.

Authors: William H Shrank; Jane F Barlow; Troyen A Brennan
Journal: JAMA Date: 2015-10-13 Impact factor: 56.272

3. Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decisionmaking about health care programs.

Authors: A Gafni
Journal: Med Care Date: 1991-12 Impact factor: 2.983

4. Heterogeneity in action: the role of passive personalization in comparative effectiveness research.

Authors: Anirban Basu; Anupam B Jena; Dana P Goldman; Tomas J Philipson; Robert Dubois
Journal: Health Econ Date: 2013-10-09 Impact factor: 3.046

5. The median isn't the message.

Authors: Stephen Jay Gould
Journal: Virtual Mentor Date: 2013-01-01

6. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.

Authors: Jeffrey L Anderson; Paul A Heidenreich; Paul G Barnett; Mark A Creager; Gregg C Fonarow; Raymond J Gibbons; Jonathan L Halperin; Mark A Hlatky; Alice K Jacobs; Daniel B Mark; Frederick A Masoudi; Eric D Peterson; Leslee J Shaw
Journal: J Am Coll Cardiol Date: 2014-03-27 Impact factor: 24.094

Measuring the Value of Pharmaceuticals in the US Health System.

1. Value-Based Payments Require Valuing What Matters to Patients.

2. New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines.

3. Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decisionmaking about health care programs.

4. Heterogeneity in action: the role of passive personalization in comparative effectiveness research.

5. The median isn't the message.

6. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.

7. Welfare implications of learning through solicitation versus diversification in health care.

8. Choosing peritoneal dialysis reduces the risk of invasive access interventions.

9. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.

Review 10. Recent Advances in Antiviral Therapy for Chronic Hepatitis C.